Xencor, Inc. (XNCR)
NASDAQ: XNCR · Real-Time Price · USD
9.69
+0.17 (1.79%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Xencor Employees
Xencor had 250 employees as of December 31, 2024. The number of employees decreased by 30 or -10.71% compared to the previous year.
Employees
250
Change (1Y)
-30
Growth (1Y)
-10.71%
Revenue / Employee
$441,972
Profits / Employee
-$930,472
Market Cap
683.48M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
XNCR News
- 5 weeks ago - Xencor Appoints Todd Simpson to Board of Directors - Business Wire
- 7 weeks ago - Xencor Reports Fourth Quarter and Full Year 2024 Financial Results - Business Wire
- 2 months ago - 20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset' - Market Watch
- 5 months ago - Xencor to Participate at Upcoming Investor Conferences - Business Wire
- 5 months ago - Xencor: Plamotamab NHL Data Leads To RA Program Advancement - Seeking Alpha
- 5 months ago - Xencor Reports Third Quarter 2024 Financial Results - Business Wire
- 5 months ago - Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease - Business Wire
- 6 months ago - Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases - Business Wire